豬肉概念股全線上漲 正邦科技(002157.SZ)逼近漲停
格隆匯3月5日丨正邦科技公佈亮眼業績快報刺激,豬肉概念股全線上漲領漲A股市場,其中,正邦科技一度逼近漲停,傲農生物、新五豐、唐人神、金新農、天康生物、温氏股份、得利斯漲幅均在5%以上。正邦科技昨日公佈,2020年2月銷售生豬34.27萬頭,環比增長14.33%,同比下降4.33%;銷售收入15.56億元,環比增長39.44%,同比增長293.89%。今年1-2月,累計銷售生豬64.24萬頭,同比下降42.76%;但累計銷售收入26.73億元,同比增長116.34%。正邦科技表示,2月生豬銷售收入環比及同比增長較大主要是由於生豬銷售價格增幅較大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.